The IMF projects El Salvador's economy to grow 4.5% in 2026 after a strong 3.9% expansion in 2025, driven by investment, consumption, remittances, tourism, and improved security. The IMF approved a $138-140 million disbursement under a $1.4 billion program supporting fiscal reforms, despite the country breaching a Bitcoin accumulation condition, granting a waiver instead of halting funds. This positive outlook reflects strengthened fiscal policies and reduced crime, boosting investor confidence and economic stability.
El Salvador's economic outlook is strong with the IMF projecting 4.5% growth in 2026 following a 3.9% expansion in 2025. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 02, 2026 06:03 WIB: out of 50 major cryptocurrencies, 25 rose and 24 fell today. Notable movers include BAL (Balancer) up 11.14% at Rp16.297 with a typical hold time of 85 days, COTI up 8.60% at Rp252 with 83% sell order activity, and AAVE up 8.53% at Rp3.092.012 with 60% buy order activity and a typical hold time of 105 days.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
